A broad body of data suggests that small molecule antagonists of the bHLH transcription factor Olig2 would have therapeutic value for both pediatric and adult astrocytomas. However transcription factors are generally considered to be unattractive targets for drug development because their interactions with DNA and with co-regulator proteins involve large and complex surface area contacts. A second major challenge - generic to any drug development project involving CNS cancers - is the blood/brain barrier. The broad goal of this project is to develop a small molecule Inhibitor of Olig2 that can cross the blood/brain barrier. Our two specific aims are to adapt a pair of innovative new methods towards this goal.
Aim one is to use """"""""stapled peptide"""""""" chemistry to generate small molecule alpha-helical mimetics that can disrupt the interaction between Olig2 and essential co-regulator proteins.
Aim two is to use MALDI mass spectrometry imaging for direct imaging of these stapled peptide mimetics within the interstitial spaces ofthe brain at a resolution of 50 um (soon to be 10 um). Our study plan will merge these two methodologies into an iterative protocol for modification of lead compounds into potent, highly specific antagonists of Olig2 with good blood/brain barrier penetrance. The study plan will be carried out by a team with skill sets in three separate fields: The Stiles lab has credentials in the area of transcription factors and neural development. Co-investigator Loren Walensky is an authority on stapled peptide chemistry. Co-investigator Nathalie Agar provides the essential expertise in MALDI mass spectrometry imaging. The study plan for this project will benefit from economies of scale enabled by the Innovative Neuropathology Core. Mutually beneficial collaborative interactions with the investigators on Project One and Project Three will insure that the ultimate contributions of this program to the field of astrocytoma research exceeds the contributions ofthe individual project components.

Public Health Relevance

Initially as tool compounds and in the fullness of time as therapeutics, the Olig2 antagonists we envision could impact research and treatment of an underserved disease - namely pediatric low-grade astrocytoma (PLGA). Moreover, small molecule inhibitors of Olig2 could serve as targeted therapeutics for a wide range of adult gliomas as well.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Filbin, Mariella G; Tirosh, Itay; Hovestadt, Volker et al. (2018) Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360:331-335
Zhou, Jing; Tien, An-Chi; Alberta, John A et al. (2017) A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep 18:3167-3177
Zhang, Jing; Gao, Xueliang; Schmit, Fabienne et al. (2017) CRKL Mediates p110?-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep 20:549-557
Ramkissoon, Shakti H; Bandopadhayay, Pratiti; Hwang, Jaeho et al. (2017) Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol 19:986-996
Sun, Yu; Alberta, John A; Pilarz, Catherine et al. (2017) A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol 19:774-785
Zhao, Xuesong; Pak, Ekaterina; Ornell, Kimberly J et al. (2017) A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO Inhibitors. Cancer Discov 7:1436-1449
Ni, Jing; Xie, Shaozhen; Ramkissoon, Shakti H et al. (2017) Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol 19:22-30
Ilic, Nina; Birsoy, K?vanç; Aguirre, Andrew J et al. (2017) PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A 114:E3434-E3443
Pak, Ekaterina; Segal, Rosalind A (2016) Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell 38:333-44
Stevens, Mark M; Maire, Cecile L; Chou, Nigel et al. (2016) Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol 34:1161-1167

Showing the most recent 10 out of 59 publications